XBP1 and ovarian carcinoma: Interestingly, based on gene expression, prognosis, and relativity to multiple immune checkpoints analyses, we found that XBP1-based therapy may show a more promising prospect for ovarian cancer immunotherapy than immune checkpoint inhibitors therapy.